EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

Trial Details

NCT ID

NCT05341492

Phase

EARLY_PHASE1

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• EGFR/B7H3 CAR-T

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening proce…
• 18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced lung cancer and triple-negative breast …
• EGFR/B7H3 expression was confirmed positive in tumor site by immunohistochemical test within 3 months before signing the informed consent form;
• According to RECIST version 1.1 of solid tumor efficacy evaluation criteria, there should be at least one measurable lesion during screening period…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.